Johnson & Johnson to buy Abiomed in $16.6 billion deal

Johnson & Johnson said connected Tuesday it volition get Abiomed successful a woody valued astatine $16.6 cardinal to boost the healthcare conglomerate's aesculapian devices business.

The upfront outgo of $380 per stock represents a 50.7% premium to Abiomed's past closing price.

Abiomed shareholders volition besides get a non-tradeable contingent worth close entitling the holder to person up to $35 per stock successful currency if definite commercialized and objective milestones are achieved.

Abiomed makes the bosom pump Impella.

This communicative is developing. Please cheque backmost for updates.